BridgeMD
New treatment option for Gastric Cancer
Official title Preventive Use of PIPAC in Locally Advanced Gastric Cancer.
ClinicalTrials.gov ID: NCT06784765
What this study is testing
- What it's testing
- Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer-related mortality. In patients with locally advanced gastric cancer, multimodal treatment strategies, including perioperative chemotherapy, have significantly improved survival rates.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults aged 18-70 years with histologically confirmed locally advanced gastric adenocarcinoma (T3-4N0-3M0), ECOG performance status 0-2, and negative...
- Signed informed consent
- Aged 18-70 years
- ECOG performance status 0-2
- Histologically confirmed adenocarcinoma of the stomach (T3-4N0-3M0)
You likely can't join if
- Presence of distant metastases
- Positive peritoneal cytology
- Previous cancer treatment (chemotherapy, radiotherapy, or surgery)
- Severe comorbid conditions contraindicating surgery or chemotherapy
- Pregnancy or lactation
- Known hypersensitivity to study drugs
See the full eligibility criteria
- Adults aged 18-70 years with histologically confirmed locally advanced gastric adenocarcinoma (T3-4N0-3M0), ECOG performance status 0-2, and negative peritoneal cytology.
- Signed informed consent
- Aged 18-70 years
- ECOG performance status 0-2
- Histologically confirmed adenocarcinoma of the stomach (T3-4N0-3M0)
- Negative peritoneal cytology from diagnostic laparoscopy
- No prior chemotherapy or radiotherapy
- Presence of distant metastases
- Positive peritoneal cytology
- Previous cancer treatment (chemotherapy, radiotherapy, or surgery)
- Severe comorbid conditions contraindicating surgery or chemotherapy
- Pregnancy or lactation
- Known hypersensitivity to study drugs
The study team makes the final eligibility decision.
Where it's taking place
- Astana, Kazakhstan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Astana, Kazakhstan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.